One option to limit the use of PRBC is to enhance hemoglobin levels perioperatively via the substitution of erythropoietin, although a study from 2009 which also included patients undergoing surgical resection of primary colorectal cancer could not derive a recommendation for such a procedure [40]. This evidence concerns the gene EPO and colorectal cancer.